MAPT and Alzheimer disease: Despite the clinical evidence of a diagnostic utility of flotillin in AD being still in its infancy, emerging findings support that it may be used in support of CSF Aβ42 and tau levels as well as PET neuroimaging for more efficient and earlier diagnosis for AD [80].